Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.67 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6796675 | 0.86 | MCHR1 (0.89) | MCHR1ACHEDRD2 | |
| Trifluoroacetic Acid SCHEMBL6799963 | 0.85 | MCHR1 (0.68) | MCHR1ACHE | |
| Trifluoroacetic Acid SCHEMBL6802111 | 0.83 | MCHR1 (0.64) | MCHR1ACHEDRD2HTR1ADRD4 | |
| Trifluoroacetic Acid SCHEMBL6800430 | 0.82 | MCHR1 (0.64) | MCHR1ACHEDRD2HTR1ADRD4 | |
| Trifluoroacetic Acid SCHEMBL6803711 | 0.82 | MCHR1 (0.64) | MCHR1ACHEDRD2 | |
| Trifluoroacetic Acid SCHEMBL6803305 | 0.82 | MCHR1 (0.63) | MCHR1ACHEDRD2HTR1ADRD4 | |
| Trifluoroacetic Acid SCHEMBL6802930 | 0.82 | DRD2 (0.62) | MCHR1ACHEDRD2HTR1ADRD4 | |
| Trifluoroacetic Acid SCHEMBL6799824 | 0.81 | MCHR1 (0.58) | MCHR1ACHEDRD2HTR1ADRD3 | |
| Trifluoroacetic Acid SCHEMBL6807608 | 0.81 | MCHR1 (0.62) | MCHR1ACHEDRD2HTR1ADRD4 | |
| Trifluoroacetic Acid SCHEMBL6801235 | 0.81 | MCHR1 (0.67) | MCHR1ACHEDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | MCHR1 191/4885ACHE 4719/4885DRD2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.